Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$62.1M, compared with -$25.78M a year earlier.
Context
- Net debt amounted to 63.0% of total assets at the end of Q1 FY2026, up 46.6 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -140.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (46.61M) USD
- Year-over-year change
- +23.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (46.61M) | +23.4% |
| FY2024 | 2024-12-31 | (60.86M) | -535.8% |
| FY2023 | 2023-12-31 | (9.57M) | +37.4% |
| FY2022 | 2022-12-31 | (15.3M) | — |
Net Debt vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 net debt of -$62.1M is the 9th highest of the 11 companies compared; the peer median is -$25.64M.
- Its year-over-year change of -140.9% is the lowest of 11, against a peer median of -17.5%.
- Net debt amounts to 63.0% of total assets for AARD, versus a peer median of 21.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $151.69M | -2.7% | — | 48.2% | |
| Mar 2026 | $14.89M | +566.3% | — | 10.0% | |
| Mar 2026 | $14.25M | +465.6% | — | 8.0% | |
| Mar 2026 | $11.02M | +55.6% | — | 17.1% | |
| Mar 2026 | -$22.66M | +81.8% | — | 22.7% | |
| Mar 2026 | -$28.63M | -40.4% | — | 12.2% | |
| Mar 2026 | -$46.92M | -79.3% | — | 21.1% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | -$56.68M | -106.8% | — | 38.9% |
| Mar 2026 | -$62.1M | -140.9% | — | 63.0% | |
| Mar 2026 | -$70.77M | -73.2% | — | 52.4% | |
ZURAZura Bio Limited | Mar 2026 | -$225.59M | -32.3% | — | 98.7% |
| Peer median (excluding AARD) | -$25.64M | -17.5% | — | 21.9% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.